Prograf

Vitiligo, Pyoderma Gangrenosum, Kidney Transplantation + 12 more

Treatment

5 FDA approvals

20 Active Studies for Prograf

What is Prograf

Tacrolimus

The Generic name of this drug

Treatment Summary

Tacrolimus (also known as FK-506 or Fujimycin) is a medicine used to prevent organ rejection after transplantation. It is also used to treat severe cases of atopic dermatitis, uveitis, and vitiligo. The drug was first discovered in 1984 from a soil sample in Japan. Tacrolimus is a macrolide that works by binding to a protein called FKBP-12, which then inhibits the activity of the immune system and reduces the risk of organ rejection.

Prograf

is the brand name

image of different drug pills on a surface

Prograf Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Prograf

Tacrolimus

1994

138

Approved as Treatment by the FDA

Tacrolimus, also called Prograf, is approved by the FDA for 5 uses such as Kidney Transplantation and Kidney Transplant Rejection .

Kidney Transplantation

Kidney Transplant Rejection

Liver Transplant Rejection

Immunosuppressive Treatment

Kidney

Effectiveness

How Prograf Affects Patients

Tacrolimus works by blocking a certain enzyme, stopping certain signals from being sent to the T-lymphocytes, and reducing the amount of a certain protein. Compared to cyclosporine, tacrolimus is more effective in reducing organ rejection. It can also be used to treat eczema, though it is not as strong as steroids. An advantage of tacrolimus is that it can be used on the face, while steroids cannot. For other parts of the body, steroids are usually the better treatment.

How Prograf works in the body

We don't know exactly how tacrolimus works to treat atopic dermatitis, but we have seen a few things. It appears to limit T-lymphocyte activation by binding to a protein called FKBP-12. This stops a process called dephosphorylation from happening, which is necessary for the formation of lymphokines. Tacrolimus also seems to reduce the production of several proteins that are involved in T-cell activation, as well as block the release of substances from mast cells and basophils. Finally, it may down-regulate the expression of FceRI on Langerh

When to interrupt dosage

The measure of Prograf is subject to the diagnosed condition, including Vitiligo, Rejection; Transplant, Kidney and Pyoderma Gangrenosum. The quantity of dosage deviates, depending on the procedure of delivery (e.g. Capsule, gelatin coated - Oral or Topical) indicated in the table below.

Condition

Dosage

Administration

Liver

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Pyoderma Gangrenosum

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Rheumatoid Arthritis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Lichen Planus, Oral

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Chronic Graft Versus Host Disease

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Lung

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Psoriasis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Immunocompromised

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Vitiligo

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Kidney Transplantation

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Prophylaxis against heart transplant rejection

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Kidney

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Immunosuppressive Treatment

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

Oral, Capsule, , Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Solution, Intravenous, Solution - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Kit, Cream, Cream - Topical, Solution - Topical

Warnings

Prograf has one contraindication, meaning that it should not be employed while encountering the conditions listed in the following table.

Prograf Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Tacrolimus may interact with Pulse Frequency

There are 20 known major drug interactions with Prograf.

Common Prograf Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Tacrolimus.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Tacrolimus.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Tacrolimus.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Tacrolimus.

Bacillus calmette-guerin substrain russian BCG-I live antigen

Major

The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Tacrolimus.

Prograf Toxicity & Overdose Risk

Taking too much of this drug can lead to blurred vision, kidney and liver damage, seizures, trembling, high blood pressure, low levels of magnesium, diabetes, high levels of potassium, itching, difficulty sleeping, and confusion. The lowest toxic dose in rats is 134-194mg/kg.

image of a doctor in a lab doing drug, clinical research

Prograf Novel Uses: Which Conditions Have a Clinical Trial Featuring Prograf?

147 active research studies are currently being conducted to assess the potential of Prograf to alleviate Oral Lichen Planus, Pyoderma Gangrenosum and refractory Rheumatoid Arthritis.

Condition

Clinical Trials

Trial Phases

Pyoderma Gangrenosum

2 Actively Recruiting

Phase 2, Phase 3

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Lichen Planus, Oral

0 Actively Recruiting

Vitiligo

7 Actively Recruiting

Phase 2, Phase 3, Phase 1

Kidney Transplantation

0 Actively Recruiting

Kidney

0 Actively Recruiting

Liver

0 Actively Recruiting

Immunosuppressive Treatment

0 Actively Recruiting

Lung

0 Actively Recruiting

Dermatitis, Atopic

0 Actively Recruiting

Prophylaxis against heart transplant rejection

0 Actively Recruiting

Psoriasis

0 Actively Recruiting

Chronic Graft Versus Host Disease

24 Actively Recruiting

Phase 4, Phase 1, Phase 2, Not Applicable, Phase 3

Dermatitis, Atopic

0 Actively Recruiting

Prograf Reviews: What are patients saying about Prograf?

5

Patient Review

5/21/2014

Prograf for Prevention of Liver Transplant Rejection

I had a kidney transplant about a year ago and have been taking Prograf since. My creatinine levels have always stayed stable between 1.3 and 1.4. But, for the last three months I've been taking Tracolimus (the generic version) and my creatinine has risen from 1.5 to 1.7. Has anyone else experienced this? Or does anyone know if this could be the problem?

5

Patient Review

8/16/2015

Prograf for Prevention of Liver Transplant Rejection

So far, I'm five weeks in and feeling good. There was a little bit of initial adjustments needed for the first hour or two, but since then it's been fine. No rejections thus far, touch wood.

5

Patient Review

2/13/2015

Prograf for Rejection of Liver Transplant

Though I experienced a range of side effects, like hair loss, tingling, blurred vision and insomnia, I'm thankful that this treatment didn't negatively impact my liver.

4.7

Patient Review

8/2/2015

Prograf for Prevention of Cardiac Transplant Rejection

It's only been three months since my liver transplant, and I was already on dialysis. However, after just six weeks I had a fever of 100.3. They found an infection in my blood.

4.7

Patient Review

1/29/2017

Prograf for Prevention of Liver Transplant Rejection

Prograf has been a life-saver for me. I had a liver transplant when I was two and a half, and have been on Prograf ever since. It's tough on my kidneys, which causes me to have high blood pressure, but I'm also taking another medication to help with that. This New Year's Eve will be my 12th "liver-versary", and I credit Prograf (along with a few other drugs) for keeping me alive all this time.

4.7

Patient Review

6/28/2016

Prograf for Prevention of Liver Transplant Rejection

For those of you who are struggling with this treatment, I just want to let you know that in most cases the doctor can switch you back to the brand name if generic is causing problems. And for those of you who have only recently started this medication, please be aware that many side effects will dissipate over time and your hair may even grow back thicker than before. This is my second transplant and I feel very lucky.

4.7

Patient Review

11/22/2017

Prograf for Prevent of Transplant Rejection

The transplant went great and I only have one complaint 13 months later. The prograf has caused some shaking and trembling in my hands.

4.7

Patient Review

4/24/2014

Prograf for Prevention of Liver Transplant Rejection

4.3

Patient Review

4/25/2014

Prograf for Prevent Kidney Transplant Rejection

I underwent a liver transplant in 2010 due to cancer caused by Hepatitis B. I've been taking Prograf since the day of my surgery, and I'm now down to 1mg twice a day. The only side effects I've experienced are high blood pressure and cold hands, which are both minor compared to the alternative.

4.3

Patient Review

6/26/2016

Prograf for Prevent Kidney Transplant Rejection

I had a double organ transplant on 1/15/2014 and it's going great. I'm 20 months post-op and feeling stronger every day.

4.3

Patient Review

3/16/2014

Prograf for Prevention of Lung Transplant Rejection

4.3

Patient Review

6/8/2014

Prograf for Prevention of Lung Transplant Rejection

I'm very pleased with this transplant. It's been six months and I haven't had any issues whatsoever.

4

Patient Review

4/13/2015

Prograf for Prevention of Lung Transplant Rejection

I've been on the Prograf and Cellcept combo for thirteen years, next week. I have diabetes as a result (but it's well-controlled), and I've had to remove some bad skin cells. I also have to urinate frequently, but that's a small price to pay for being alive today.

4

Patient Review

11/21/2017

Prograf for Prevent Kidney Transplant Rejection

This medication caused my hair to fall out and also made me shake.

3.7

Patient Review

5/29/2015

Prograf for Prevention of Liver Transplant Rejection

Lots of side effects - tremors in hands and feet, but worse - loss of hair.

3.7

Patient Review

6/28/2014

Prograf for Prevention of Lung Transplant Rejection

I've had to deal with some pretty severe side-effects from this medication, but it's been worth it for the almost ten years that I've been able to tolerate it. My doctor is careful and attentive, which makes all the difference.

3.3

Patient Review

8/4/2014

Prograf for Prevention of Liver Transplant Rejection

I've been taking this medication for nearly a decade and, while there are some side effects that come with it (e.g. shaking hands), it's still better than the alternative treatments out there.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about prograf

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Prograf used to treat?

"Tacrolimus is a drug that suppresses the immune system and is used to prevent organ rejection in children who have had liver transplants."

Answered by AI

Is Prograf an immunosuppressant?

"Today's decision represents the first time an immunosuppressant drug has been approved to prevent rejection in adult and pediatric patients who receive lung transplants. Prograf is the only drug product of its kind that has been approved for this population."

Answered by AI

What are the side effects for Prograf?

"The most common adverse reactions (occurring in more than 40% of PROGRAF-treated liver transplant patients) include: tremor, headache, diarrhea, hypertension, nausea, abnormal renal function, abdominal pain, insomnia, paresthesia, anemia, pain, fever, asthenia, hyperkalemia, hypomagnesemia, and hyperglycemia."

Answered by AI

Is Prograf a steroid?

"Tacrolimus (Prograf) does not belong to the class of drugs called steroids or corticosteroids. Sometimes, corticosteroids and calcineurin inhibitors are used together to prevent transplant rejections."

Answered by AI

Clinical Trials for Prograf

Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

Ruxolitinib for T-Cell Lymphoma

18+
All Sexes
Columbus, OH

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Phase 2
Recruiting

Ohio State University Comprehensive Cancer Center

Jonathan Brammer, MD

Incyte Corporation

Have you considered Prograf clinical trials?

We made a collection of clinical trials featuring Prograf, we think they might fit your search criteria.
Go to Trials
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.

Phase 4
Waitlist Available

Sunnybrook Health Sciences Centre (+4 Sites)

Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY

The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention

Recruiting
Has No Placebo

Weill Cornell Medical College

Iris Y Navarro-Millán, MD

Bristol-Myers Squibb

Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Waitlist Available
Has No Placebo

Humana Healthcare Research, Inc. (+1 Sites)

Have you considered Prograf clinical trials?

We made a collection of clinical trials featuring Prograf, we think they might fit your search criteria.
Go to Trials
Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN

The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.

Recruiting
Drug

University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases (+4 Sites)

Daniel Zachs

SecondWave Systems Inc.

Have you considered Prograf clinical trials?

We made a collection of clinical trials featuring Prograf, we think they might fit your search criteria.
Go to Trials